186 related articles for article (PubMed ID: 30612400)
61. Kinetics of
Murbach B; Duarte G; Palma LC; Miranda E; Duffles G; Furlin GP; Toni I; De Souza C; Binelli L; Bassan VL; de Castro FA; de Figueiredo-Pontes LL; Pagnano KBB
Front Oncol; 2024; 14():1393191. PubMed ID: 38779092
[TBL] [Abstract][Full Text] [Related]
62. Assessment of molecular response to tyrosine kinase inhibitors in Tunisian Patients with Chronic Myeloid Leukemia.
Frikha R; Kassar O; Elloumi M; Kamoun H
J Oncol Pharm Pract; 2022 Dec; 28(8):1826-1831. PubMed ID: 34846219
[TBL] [Abstract][Full Text] [Related]
63. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Flygt H; Sandin F; Dahlén T; Dremaine A; Lübking A; Markevärn B; Myhr-Eriksson K; Olsson K; Olsson-Strömberg U; Själander A; Söderlund S; Wennström L; Wadenvik H; Stenke L; Höglund M; Richter J
Br J Haematol; 2021 Jun; 193(5):915-921. PubMed ID: 33782950
[TBL] [Abstract][Full Text] [Related]
64. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
65. Treatment-free remission in patients with chronic myeloid leukemia.
Rea D; Cayuela JM
Int J Hematol; 2018 Oct; 108(4):355-364. PubMed ID: 28689264
[TBL] [Abstract][Full Text] [Related]
66. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
67. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
68. [Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
Geng SX; Weng JY; Huang X; Lu ZS; Wu P; Huang LS; Liu L; Du X
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):561-5. PubMed ID: 23906446
[TBL] [Abstract][Full Text] [Related]
69. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
70. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.
Voglova J; Muzik J; Faber E; Zackova D; Klamova H; Steinerova K; Michalovicova Z; Demitrovicova L; Cmunt E; Novakova L; Tothova E; Belohlavkova P; Mayer J; Indrak K
Neoplasma; 2011; 58(3):256-62. PubMed ID: 21395367
[TBL] [Abstract][Full Text] [Related]
71. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
Elsayed AG; Srivastava R; Jamil MO
Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389
[TBL] [Abstract][Full Text] [Related]
72. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
73. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
74. Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
McMullan RR; McConville C; McMullin MF
Ulster Med J; 2019 May; 88(2):105-110. PubMed ID: 31061559
[TBL] [Abstract][Full Text] [Related]
75. [Molecular mechanisms in the resistance of CML stem cells to tyrosine kinase inhibitors and novel targets for achieving a cure].
Tanaka H; Hirase C; Matsumura I
Rinsho Ketsueki; 2015 Feb; 56(2):139-49. PubMed ID: 25765793
[TBL] [Abstract][Full Text] [Related]
76. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
[TBL] [Abstract][Full Text] [Related]
77. [Fertility and disease outcomes in patients with chronic myeloid leukemia].
Dou XL; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):980-985. PubMed ID: 32023726
[No Abstract] [Full Text] [Related]
78. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
79. Discontinuation of TKI therapy and 'functional' cure for CML.
Mahon FX
Best Pract Res Clin Haematol; 2016 Sep; 29(3):308-313. PubMed ID: 27839571
[TBL] [Abstract][Full Text] [Related]
80. [Efficacy of tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients].
Li XL; Zhu HL; Liu HY; Lü SJ; Zheng SP; Wu Y; Niu T; Liu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):647-51. PubMed ID: 25286693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
